Announcements

Pre Dec 2020 Announcements

Hexima Limited lists on ASX

Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing a new prescription treatment for onychomycosis (fungal nail infection), will list on the Australian Securities Exchange...

Shareholder Announcement

Hexima Limited has released a shareholder announcement with updates on the following: Lodgment of Prospectus with ASIC Management and Board of Director Changes  First Patient Treated in Phase IIb...

Update on Hexima’s development program

Dear Shareholder, I am writing to you to provide an update on Hexima’s development program. Hexima’s lead product (HXP124) is a topical treatment for nail fungus (onychomycosis). HXP124 is an easy...